Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell-based medicines for the treatment of life-threatening diseases, entered into a definitive agreement under which Sanofi will make a public offer to acquire the entire share capital of Kiadis for approximately $359 million.   “We believe the Kiadis ‘off the shelf’ K-NK cell technology platform will have broad application against liquid and solid tumors, and create synergies ...